Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

GHSG-AFM13 An Open-label, Randomized, Multicenter Phase II Trial With AFM13 in Patients With Relapsed or Refractory Hodgkin Lymphoma

NCT02321592 is registered in ClinicalTrials.gov with University of Cologne as lead sponsor.

NCT NCT02321592
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02321592 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
GHSG-AFM13 An Open-label, Randomized, Multicenter Phase II Trial With AFM13 in Patients With Relapsed or Refractory Hodgkin Lymphoma
Lead sponsor
University of Cologne
Phase
Phase 2
Overall status
Completed
Start date
May 31, 2015
Completion date
July 31, 2020
Enrollment
23 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

hodgkin lymphoma